Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 10;19(9):2685.
doi: 10.3390/ijms19092685.

Uremic Toxins Activates Na/K-ATPase Oxidant Amplification Loop Causing Phenotypic Changes in Adipocytes in In Vitro Models

Affiliations

Uremic Toxins Activates Na/K-ATPase Oxidant Amplification Loop Causing Phenotypic Changes in Adipocytes in In Vitro Models

David E Bartlett et al. Int J Mol Sci. .

Abstract

Background: Oxidant stress plays a key role in the development of chronic kidney disease (CKD). Experimental CKD leads to accumulation of uremic toxins (UT) in the circulation resulting in increased ROS production, which in turn, is known to activate the Na/K-ATPase/ROS amplification loop. Studies in a murine model of obesity have shown that increased oxidative stress in plasma is due to increased ROS and cytokine production from dysfunctional adipocytes. Therefore, we hypothesized that adipocytes exposed to UTs will activate the Na/K-ATPase oxidant amplification loop causing redox imbalance and phenotypic alterations in adipocytes. We also aimed to demonstrate that the Na/K-ATPase signaling antagonist, pNaKtide, attenuates these pathophysiological consequences.

Methods: In the first set of experiments, 3T3-L1 murine pre-adipocytes were treated with varying concentrations of UTs, indoxyl sulfate (IS) (50, 100 and 250 µM) and p-cresol (50, 100 and 200 µM), with or without pNaKtide (0.7 µM) for five days in adipogenic media, followed by Oil Red O staining to study adipogenesis. RT-PCR analysis was performed to study expression of adipogenic, apoptotic and inflammatory markers, while DHE staining evaluated the superoxide levels in UT treated cells. In a second set of experiments, visceral fat was obtained from the West Virginian population. MSCs were isolated and cultured in adipogenic media for 14 days, which was treated with indoxyl sulfate (0, 25, 50 and 100 µM) with or without pNaKtide (1 µM). MSC-derived adipocytes were evaluated for morphological and molecular analysis of the above markers.

Results: Our results demonstrated that 3T3-L1 cells and MSCs-derived adipocytes, treated with UTs, exhibited a significant decrease in adipogenesis and apoptosis through activation of the Na/K-ATPase/ROS amplification loop. The treatment with pNaKtide in 3T3-L1 cells and MSC-derived adipocytes negated the effects of UTs and restored cellular redox in adipocytes. We noted a varying effect of pNaKtide, in adipocytes treated with UTs, on inflammatory markers, adipogenic marker and superoxide levels in 3T3-L1 cells and MSC-derived adipocytes.

Conclusions: This study demonstrates for the first time that the Na/K-ATPase/ROS amplification loop activated by elevated levels of UTs has varying effect on phenotypic alterations in adipocytes in various in vitro models. Thus, we propose that, if proven in humans, inhibition of Na/K-ATPase amplification of oxidant stress in CKD patients may ultimately be a novel way to combat adipocyte dysfunction and metabolic imbalance in these patients.

Keywords: CKD; Na/K-ATPase signaling; ROS; adipocytes; oxidative stress; uremic toxins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Dose dependent effect of IS exposed to 3T3-L1 murine pre-adipocytes and treated with or without pNaKtide: (A) representative images and quantitative data of adipogenesis measured as the relative absorbance of Oil Red O. Images taken with 40× objective lens; (B) quantitative analysis of pro-inflammatory cytokine IL-6; and (C) MTT assay represented as percentage of control. Values represent means ± SEM (n = 6). * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR, + p < 0.05 vs. IS 100 µM, ++ p < 0.01 vs. IS 100 µM, # p < 0.05 vs. pNaKtide.
Figure 2
Figure 2
(A) Effect of IS 100 µM in 3T3-L1 cells treated with or without pNaKtide for superoxide levels assessed with DHE staining; (B) RT PCR analysis for the expression of adipogenic marker PPARϒ; (C) representative Western blots for Src activation; (D) RT PCR analysis for the expression of pro-inflammatory markers TNF-α and MCP-1; and (E) RT PCR analysis for the expression of pro-apoptotic markers Bax and Caspase 3. Values represent means ± SEM (n = 6). * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR, # p < 0.05 vs. pNaKtide, ## p < 0.01 vs. pNaKtide, + p < 0.05 vs. IS, ++ p < 0.01 vs. IS.
Figure 3
Figure 3
Dose-dependent effect of p-cresol exposed to 3T3-L1 murine pre-adipocytes and treated with or without pNaKtide. (A) Representative images and quantitative data of adipogenesis measured as the relative absorbance of Oil Red O. Images taken with 40× objective lens; (B) quantitative analysis of pro-inflammatory cytokine IL-6; and (C) MTT assay. Values represent means ± SEM (n = 6). * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR, ++ p < 0.01 vs. p-cresol 100 µM, # p < 0.05 vs. pNaKtide.
Figure 4
Figure 4
(A) Effect of p-cresol 100 µM in 3T3-L1 cells treated with or without pNaKtide for superoxide levels assessed with DHE staining; (B) RT PCR analysis for the expression of adipogenic marker, PPARϒ; (C) representative Western blots for Src activation; (D) RT PCR analysis for the expression of pro-inflammatory markers TNF-α and MCP-1; and (E) RT PCR analysis for the expression of pro-apoptotic markers, Bax and Caspase 3. Values represent means ± SEM (n = 6). * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR, # p < 0.05 vs. pNaKtide, ## p < 0.01 vs. pNaKtide, + p < 0.05 vs. p-cresol, ++ p < 0.01 vs. p-cresol.
Figure 5
Figure 5
MSC-derived adipocytes exposed to varying concentrations of IS (25, 50 and 100 µM) and treated with or without pNaKtide: (A) Representative images and quantitative data of adipogenesis measured as the relative absorbance of Oil Red O. Images taken with 40× objective lens; and (B) quantitative analysis of pro-inflammatory cytokine IL-6. Values represent means ± SEM (n = 4). * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR, + p < 0.05 vs. IS 50 µM, ++ p < 0.01 vs. IS 50 µM, # p < 0.05 vs. pNaKtide.
Figure 6
Figure 6
(A) MSC-derived adipocytes exposed to IS 50 µM and treated with or without pNaKtide on superoxide levels assessed with DHE staining; (B) RT PCR analysis for the expression of adipogenic marker PPARϒ; (C) RT PCR analysis for the expression of pro-inflammatory markers TNF-α and MCP-1; and (D) RT PCR analysis for the expression of pro-apoptotic markers Bax and Caspase 3. Values represent means ± SEM (n = 4). * p < 0.05 vs. CTR, ** p < 0.01 vs. CTR, ## p < 0.01 vs. pNaKtide, + p < 0.05 vs. IS, ++ p < 0.01 vs. IS.
Figure 7
Figure 7
Schematic representation of Na/K-ATPase oxidant amplification loop-mediated phenotypic alterations in adipocytes, induced by the UTs in 3T3-L1 cells and MSCs-derived adipocytes.

Similar articles

Cited by

References

    1. Fraser S.D., Blakeman T. Chronic kidney disease: Identification and management in primary care. Pragmat. Obs. Res. 2016;7:21–32. doi: 10.2147/POR.S97310. - DOI - PMC - PubMed
    1. Wang X., Liu J., Drummond C.A., Shapiro J.I. Sodium potassium adenosine triphosphatase (Na/K-ATPase) as a therapeutic target for uremic cardiomyopathy. Expert Opin. Ther. Targets. 2017;21:531–541. doi: 10.1080/14728222.2017.1311864. - DOI - PMC - PubMed
    1. Moradi H., Sica D.A., Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am. J. Nephrol. 2013;38:136–148. doi: 10.1159/000351758. - DOI - PubMed
    1. Baud L., Ardaillou R. Reactive oxygen species: Production and role in the kidney. Pt 2Am. J. Physiol. 1986;251:F765–F776. doi: 10.1152/ajprenal.1986.251.5.F765. - DOI - PubMed
    1. Modaresi A., Nafar M., Sahraei Z. Oxidative stress in chronic kidney disease. Iran. J. Kidney Dis. 2015;9:165–179. - PubMed

MeSH terms